Victory Capital Management Inc. Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Victory Capital Management Inc. cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 94,670 shares of the medical research company’s stock after selling 10,493 shares during the quarter. Victory Capital Management Inc.’s holdings in IQVIA were worth $21,905,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of IQV. Berry Wealth Group LP purchased a new position in shares of IQVIA during the 4th quarter worth $531,000. Brighton Jones LLC purchased a new position in IQVIA during the fourth quarter worth about $201,000. Mission Wealth Management LP purchased a new stake in IQVIA in the 4th quarter valued at about $360,000. Silver Oak Securities Incorporated increased its stake in shares of IQVIA by 1,046.8% during the 4th quarter. Silver Oak Securities Incorporated now owns 2,844 shares of the medical research company’s stock valued at $658,000 after acquiring an additional 2,596 shares during the last quarter. Finally, Stonebrook Private Inc. purchased a new position in shares of IQVIA during the 4th quarter worth about $706,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Down 0.5 %

Shares of NYSE:IQV opened at $227.88 on Thursday. The company has a market capitalization of $41.52 billion, a price-to-earnings ratio of 31.13, a price-to-earnings-growth ratio of 2.16 and a beta of 1.52. The company has a 50 day moving average of $243.28 and a two-hundred day moving average of $225.03. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The business had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. During the same period last year, the business earned $2.54 EPS. The business’s revenue was up 3.5% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Barclays increased their target price on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Truist Financial lowered their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, Evercore ISI decreased their target price on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, May 3rd. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $257.57.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.